Peter Dull

Dr. Peter Dull provides technical and strategic guidance on clinical vaccine development to various foundation teams and external partners. He also leads the foundation’s investments in human papillomavirus vaccines, including as part of reduced dose schedules.

Peter joined the foundation in 2014 after 10 years at Novartis, where he was the clinical franchise head for meningitis and sepsis vaccines. In that role, he led the clinical development and global licensure of a quadrivalent meningococcal glycoconjugate vaccine (Menveo, or MenACWY-CRM) as well as a protein-based serogroup B meningococcal vaccine (Bexsero, or 4CMenB). His work also included early clinical development of group B strep glycoconjugate and Staphylococcus aureus vaccines.

Before joining Novartis, Peter was an epidemic intelligence service officer in the Meningitis and Special Pathogens Branch of the U.S. Centers for Disease Control and Prevention.

Peter received a medical degree at University of Wisconsin–Madison. He completed internal medicine training at Oregon Health Sciences University and subspecialty training in infectious diseases at Emory University.